Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7Thoracic 2Other solid neoplasm 2Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 378Pituitary Neoplasms 158Multiple Endocrine Neoplasia Type 1 150Thyroid Cancer, Papillary 122Pheochromocytoma 107Carcinoma, Neuroendocrine 93Thyroid Neoplasms 74Paraganglioma 68Carcinoid Tumor 66Neoplasms 54Thyroid Carcinoma, Anaplastic 50Adrenocortical Carcinoma 47Adrenal Gland Neoplasms 46Neoplasm Metastasis 40Insulinoma 39Pancreatic Neoplasms 36Gastro-enteropancreatic neuroendocrine tumor 36Adenoma, Islet Cell 36Carcinoma, Medullary 29Neuroblastoma 28Adenocarcinoma, Follicular 28Hyperaldosteronism 25Prostatic Neoplasms 24Lung Neoplasms 24Obesity 23Brain Neoplasms 22Pituitary Diseases 21Differentiated Thyroid Cancer 20Cushing Syndrome 20Sarcoma 19

Interventions

atezolizumab 1Immunoglobulin G 1Disulfides 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma, Mucinous × Endocrine × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡